| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Takuya Sho, Kenichi Morikawa, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Mugumi Kimura, Masato Nakai, Goki Suda, Mitsuteru Natsuizaka, Koji Ogawa and Naoya Sakamoto |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Japan Agency for Medical Research and Development |
JP20fk0210053 |
| the Japan Agency for Medical Research and Development |
JP20fk0310103 |
| the Japan Agency for Medical Research and Development |
JP20fk0210072 |
| the Japan Agency for Medical Research and Development |
JP20fk0210056 |
| the Japan Agency for Medical Research and Development |
JP20fk0310101 |
| the Japan Agency for Medical Research and Development |
20fk0210067 |
| JSPS KAKENHI |
JP20K08371 |
| JSPS KAKENHI |
JP19K18956 |
|
| Corresponding Author |
Kenichi Morikawa, MD, PhD, Assistant Professor, Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Kita 15 Nishi 7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan. kenichi.morikawa@med.hokudai.ac.jp |
| Key Words |
Hepatocellular carcinoma; Lenvatinib; Molecular targeted agent; TACE-refractory; TACE-unsuitable; Barcelona Clinic Liver Cancer intermediate stage |
| Core Tip |
For about 10 years, first-line systemic chemotherapy for patients with advanced hepatocellular carcinoma (HCC) had been limited to sorafenib. The Phase III clinical trial of lenvatinib for patients with advanced HCC showed lenvatinib to be non-inferior to sorafenib with respect to overall survival (OS). The OS of patients is still far from satisfactory, and there is a great unmet medical need for more effective therapies. This review focuses on the current understanding of the therapeutic efficacy and safety of lenvatinib in the world and outlines the role of lenvatinib in the new era of chemotherapy for HCC. |
| Publish Date |
2021-12-14 23:58 |
| Citation |
Sho T, Morikawa K, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. World J Gastrointest Oncol 2021; 13(12): 2076-2087 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i12/2076.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i12.2076 |
